3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

58.90 -1.22 ( -2.03% ) 4:02 7/19/18 Pricing delayed 20 minutes

Volume 629,394

Recent News

See All
July 19, 2018 Nevro to Report Operating Results for the Second Quarter 2018
Nevro to Host Conference Call on Thursday, August 2, 2018 at 1:30 p.m. PT / 4:30 p.m. ET  Nevro Corp. (NYSE: NVRO), a global medical technology company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the second quarter of 2018 after market close on Thursday, August 2, 2018. Company management will host a conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, August 2, 2018. Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers or (734) 385-2616 for international callers (Conference ID: 9865398), or logging into the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global...
July 16, 2018 Nevro Announces Preliminary Unaudited Second Quarter 2018 Revenue and Updates Full Year 2018 Revenue Guidance
Company to Host Conference Call Today, Monday, July 16, 2018 at 5:30 a.m. PT / 8:30 a.m. ET  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced preliminary unaudited revenue for the second quarter ended June 30, 2018. The company announced that preliminary unaudited second quarter 2018 worldwide revenue is expected to be approximately $96.1 million, compared to $78.0 million in the second quarter of 2017. Preliminary unaudited U.S. revenue for the second quarter of 2018 is expected to be approximately $79.9 million. Preliminary unaudited international revenue for the second quarter of 2018 is expected to be approximately $16.2 million. The company expects worldwide revenue for the full year 2018 to be in the range of $385.0 to $390.0 million. This compares to previous expectations for 2018 worldwide revenue in the range of $400.0 to $410.0 million, as announced in May 2018....
July 13, 2018 Nevro to Announce Preliminary Second Quarter Worldwide Revenue, Discuss Full Year 2018 Revenue Guidance and Provide Business Updates
Company to Host Conference Call on Monday, July 16, 2018 at 5:30 a.m. PT / 8:30 a.m. ET  Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that its management will be hosting a business update conference call before market open beginning at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) on Monday, July 16, 2018. Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers or (734) 385-2616 for international callers (Conference ID: 2196519), or logging into the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.